Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725961 | PMC |
| http://dx.doi.org/10.1016/j.ekir.2024.11.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Eculizumab Discontinuation in Atypical Hemolytic Uremic Syndrome: A Systematic Review and Meta-analysis.
Blood Adv
August 2025
Medical University of South Carolina, Charleston, South Carolina, United States.
Atypical hemolytic uremic syndrome (aHUS), a life-threatening complement-mediated disorder, is now treatable with terminal complement inhibitors like eculizumab. Although effective, these therapies are costly and increase susceptibility to infections, notably meningococcal disease, raising concerns about long-term use. The optimal duration of complement inhibition remains unclear, prompting efforts to explore the possibility of treatment discontinuation.
View Article and Find Full Text PDF[Treatment strategies for autoimmune hemolytic anemia].
Rinsho Ketsueki
August 2025
Department of Hematology, Fukushima Medical University.
Autoimmune hemolytic anemia (AIHA), which is caused by autoantibodies for red blood cell membrane antigens, is categorized into two forms: warm AIHA, which involves warm antibodies, and cold agglutinin disease (CAD), which involves hemolysis and red blood cell agglutination due to cold agglutinins. The first-line therapy for wAIHA is corticosteroids. Clinical guidelines by the British Society for Haematology recommend rituximab as second-line therapy, but Japanese national health insurance does not cover rituximab for wAIHA.
View Article and Find Full Text PDFIntercepting the complement amplification loop through podocyte MC5R signaling ameliorates membranous nephropathy.
Mol Ther
July 2025
Division of Nephrology, Department of Medicine, University of Toledo College of Medicine, Toledo, OH, USA. Electronic address:
Melanocortin therapy has demonstrated potential in improving membranous nephropathy in human patients. The underlying mechanisms remain unclear. Here, in a heterologous mouse model of THSD7A-associated membranous nephropathy, various melanocortin agents, including repository corticotropin injection, the nonsteroidogenic pan-melanocortin receptor agonist NDP-MSH, and the selective melanocortin 5 receptor (MC5R) agonist PG-901, attenuated proteinuria, and ameliorated glomerulopathy.
View Article and Find Full Text PDFInfluenza A H1N1 Triggering Complement-Mediated Hemolytic Uremic Syndrome.
J Med Cases
July 2025
Department of Medicine, Brown University, Providence, RI 02912, USA.
Complement-mediated hemolytic uremic syndrome (CM-HUS) is a condition characterized by hemolytic anemia, thrombocytopenia, and renal impairment, typically associated with a chronic dysregulation of the complement system. Few adult cases of CM-HUS triggered by influenza infection have been described. Here we present a case of a 56-year-old female with multiple myeloma receiving cancer treatment who presented with Influenza A H1N1-associated CM-HUS.
View Article and Find Full Text PDFRenal Thrombotic Microangiopathy due to Hypertensive Emergency.
Case Rep Nephrol
July 2025
Department of Internal Medicine, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Thrombotic microangiopathy (TMA) is characterized by microvascular thrombosis, microangiopathic hemolytic anemia (MAHA), and thrombocytopenia. TMA can lead to acute kidney injury (AKI) due to the formation of thrombi within the renal microvasculature causing ischemic injury. AKI in the setting of TMA requires early recognition, comprehensive serologic evaluation, and timely intervention due to the risk of irreversible renal damage.
View Article and Find Full Text PDF